To test this, we examined the cross-presentation capacity of DCs by performing an IFN-γ–based ELISPOT assay using DCs isolated from tumor-draining lymph nodes (TDLNs) of B16-OZ tumor–bearing mice. This evidence concerns the gene IFNG and neoplasm.